Gliosarcoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Gliosarcoma (GS) is a primary mixed tumor in the central nervous system that has a biphasic pattern consisting of glial and malignant mesenchymal elements. It manifests through various symptoms, including headaches, seizures, memory problems, thought process issues, movement difficulties, and numbness or weakness. The onset of GS is usually observed in individuals aged between the fourth and sixth decade of life, and the male/female ratio is 1.8/1. Gliosarcomas are classified as Grade IV tumors, which grow rapidly and spread aggressively. They may be primary or secondary, based on their origin. Primary gliosarcomas originate in the central nervous system, while secondary gliosarcomas arise after the initial treatment of another glioblastoma, usually following radiation therapy. Gliosarcomas are rare, accounting for approximately 2% of all glioblastomas, and both tumor types are challenging to treat because they tend to grow aggressively and invade surrounding brain tissues. The treatment of GS comprises surgical resection of the tumor, external radiotherapy, and chemotherapy in some cases.
·
In the USA, the incidence rate of Gliosarcoma
was estimated to be 3.19 per 100,000 individuals annually.
Thelansis’s “Gliosarcoma Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022
To 2032" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Gliosarcoma treatment modalities options
for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and
China).
KOLs insights
of Gliosarcoma across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Gliosarcoma Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment